Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accessible, Actemra, added, additio, adver, afl, aining, alized, als, annua, ant, app, ARCA, ARCALY, armaceutical, art, AstraZ, ation, atrial, att, autoimmunity, avascular, bad, biology, bo, breast, BristolMyersSquibb, brought, burn, canceling, chart, chieved, christine, cial, codified, collabo, College, comm, commerciali, compensa, complaint, compression, conn, contr, conver, coronary, correctly, counterclaim, ctive, de, deciliter, declaratory, deprec, discon, eceiving, ecember, echnology, econd, ection, ed, ee, Effe, egistration, egree, elderly, eleven, EMA, endorse, eneca, England, er, ercialization, escalating, escalation, essential, esult, expressly, fibrillation, FIFO, finan, fo, frequency, furt, gation, gave, GF, great, headache, hese, highest, hus, hypercholesterolemia, hyperemia, hyperlipidemic, iation, ibercept, ibody, ibuted, icted, id, idered, IgE, Immunoglobulin, incl, indomethacin, infarction, ing, ith, judged, lan, landmark, le, likelihood, link, lizing, loading, LYST, McMaster, Medica, men, ment, mid, missta, motion, mpared, myocardial, myopia, nal, natively, ncompetitive, ncy, nducted, neovascularisation, nominal, notab, nov, novation, NRS, Numeric, numerically, obli, Occupa, Ontario, operat, ophthalmic, ound, ov, pa, Paradoxically, pathologic, PCAOB, ph, pharmacology, physiology, poon, population, PPACA, preclude, precluding, rarily, ration, reatment, reconciliation, reimb, remodeling, Researc, respiratory, restr, reward, Rheumatology, rmation, robustly, root, roval, run, RVO, sanof, securit, sely, sensory, SERI, Servier, shelf, Simponi, Singapore, solution, Southern, ST, stable, strongly, stud, subcutaneously, successo, team, tech, tement, teriorate, thereof, tible, til, tinuation, tion, tool, tract, ts, uding, udited, undisclosed, unrecognized, upper, urate, ursed, uti, vario, VE, VelociMo, VelociSuiteTM, waiver, walking, Wall, weekly, Western, wit, WOMAC, ze
Removed:
adjustment, aim, AOC, API, applying, base, chronic, clinically, commitment, competitor, consortium, cryopyrin, description, fee, identifying, initially, leakage, ligand, likewise, listing, malignant, misstatement, move, Multisystem, Neonatal, NOMID, Onset, ovarian, partially, permeability, point, potent, promulgated, reformulated, regulator, restriction, revision, robust, shipped, SMA, Society, supplied, symptomatic, thousand, unearned, unrestricted, upfront, validating, VPF
Filing tables
Filing exhibits
- 10-K Annual report
- 10.1.7 Form of Restricted Stock Award Agreement and Related Notice of Grant
- 10.1.8 Form of Option Agreement and Related Notice of Grant
- 10.11.7 Seventh Amendment to Lease
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
REGN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, and 333-169569) and on Form S-3 (No. 333-169786) of Regeneron Pharmaceuticals, Inc., of our report dated February 17, 2011 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
New York, New York
February 17, 2011
February 17, 2011